Eris Lifesciences was up 1.48% to Rs 519.90 at 10:01 IST on the BSE after the company said its board will consider share buyback on 3 July 2019.
The announcement was made after market hours yesterday, 24 June 2019.
Meanwhile, the S&P BSE Sensex was down by 3.98 points, or 0.01% to 39,118.98.
On the BSE, 4765 shares were traded in the counter so far compared with average daily volumes of 596 shares in the past two weeks. The stock had hit a high of Rs 539 and a low of Rs 516.95 so far during the day. It hit a 52-week high of Rs 798.80 on 27 August 2018 and a 52-week low of Rs 475 on 19 June 2019.
On a consolidated basis, Eris Lifesciences' net profit fell 3.9% to Rs 53.88 crore on a 1.5% rise in the net sales to Rs 211.09 crore in Q4 March 2019 over Q4 March 2018.
Eris Lifesciences is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian pharmaceutical market.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app